NEW YORK, NY / ACCESSWIRE / October 2, 2018 / U.S. equities were mixed on Monday after the U.S. and Canada agreed to revise the current North American Free Trade Agreement. The Dow Jones Industrial Average gained 0.73 percent to close at 26,651.21, while the S&P 500 Index closed 0.36 percent higher at 2,924.59. The Nasdaq Composite Index dropped 0.11 percent to close at 8,037.30.
"The biggest risk factor [in the market] is a trade war and we've dialed that down a bit," according to Mike Bailey, director of research at FBB Capital Partners. "I'm not calling for a major correction or a bear market, but I think we're getting a bit ahead of ourselves here,” Bailey added.
RDI Initiates Coverage on:
ARCA biopharma, Inc.
ARCA biopharma's stock jumped 82.14% Monday, to close the day at $1.02. The stock recorded a trading volume of 8,229,749 shares, which was above its three months average volume of 901,341 shares. In the last year, ARCA biopharma's shares have traded in a range of 0.45 - 2.00. The share price has gained 126.67% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.58 is above its 200-day moving average of $0.57. Shares of ARCA biopharma have gained roughly 64.52 percent in the past month and are down 24.44 percent year-to-date.
Access RDI's ARCA biopharma, Inc. Research Report at:
On Monday, shares of Nektar Therapeutics recorded a trading volume of 4,892,583 shares, which was above the three months average volume of 2,001,228 shares. The stock ended the day 7.07% lower at $56.65. The share price has fallen 49.13% from its 52 week high with a 52 week trading range of 22.72 - 111.36. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $62.30 is below its 200-day moving average of $69.99. Shares of the company are trading at a Price to Earnings ratio of 10.54. Shares of Nektar Therapeutics have fallen roughly 14.8 percent in the past month and are down 5.14 percent year-to-date.
Access RDI's Nektar Therapeutics Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.